Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 68

Sort by

Sort Order Select

Journal Articles

Clinical Activity and Safety of the Oral ATR Inhibitor Ceralasertib (AZD6738) in Patients with MDS or CMML after Prior HMA Therapy

Andrew M. Brunner, Yiwen Liu, Jacqueline S. Garcia, Lourdes Mendez, Catherine Gutierrez, Philip C. Amrein, Rupa Narayan, Rahul Vedula, Donna S. Neuberg, Marcio Andrade-Campos, Simon Smith, Richard M Stone, Amir T. Fathi, Matthew J. Walter, Timothy Aaron Graubert, Meagan Jacoby

Blood (2024) 144 (Supplement 1): 1833.

https://doi.org/10.1182/blood-2024-195793

Published: 2024

Journal Articles

Retrospective Single-Institution Review of Bosutinib Dose Optimization for Efficacy and Safety with Dose Ramp-up and Titration

Jessica Freydman, David Sirignano, Philip C. Amrein, Meghan Bergeron, Andrew M. Brunner, Elsie Foster, Amir T. Fathi, Timothy Aaron Graubert, Hanno Hock, Michelle Hyunju Lee, Jenna Moran, Rupa Narayan, Gabriela S. Hobbs

Blood (2024) 144 (Supplement 1): 6591.

https://doi.org/10.1182/blood-2024-203629

Published: 2024

Journal Articles

CDK9 Inhibition Sensitizes TP53 Mutated AML to Standard Chemotherapy

Elizabeth C. Trull, David B. Sykes, Philip C. Amrein

Blood (2024) 144 (Supplement 1): 5800.

https://doi.org/10.1182/blood-2024-200762

Published: 2024

Journal Articles

TRK Protein Expression in TP53 Altered Acute Erythroid Leukemia

Rupa Narayan, Ronan T. Swords, Philip C. Amrein, Andrew M. Brunner, Gabriela S. Hobbs, Hanno Hock, Michelle Hyunju Lee, Timothy Aaron Graubert, Amir T. Fathi, Robert P Hasserjian, Valentina Nardi

Blood (2024) 144 (Supplement 1): 6154.

https://doi.org/10.1182/blood-2024-211201

Published: 2024

Journal Articles

Safety and Activity of the TIM3 Inhibitor Sabatolimab in Patients with Lower-Risk Myelodysplastic Syndromes

Andrew M. Brunner, Yiwen Liu, Rupa Narayan, Michelle Hyunju Lee, Philip C. Amrein, Hanno Hock, Gabriela S. Hobbs, Donna S. Neuberg, Timothy Aaron Graubert, Amir T. Fathi

Blood (2024) 144 (Supplement 1): 6726.

https://doi.org/10.1182/blood-2024-196718

Published: 2024

Journal Articles

Single-Cell Multiomics Analysis Reveals Potential Drivers of Response to the Anti-TIM3 Inhibitor Sabatolimab Combined with Azacitidine in MDS and CMML

Aonkon Dey, Rupa Narayan, Neal Smith, Alice Tirard, Benjamin Arnold, John McGuire, Thomas Chan, Jennifer Lombardi Story, Timothy Casson, Tanya Toni Behnan, Amir T. Fathi, Gabriela S. Hobbs, Hanno Hock, Philip C. Amrein, Patrick Reeves, Timothy Aaron Graubert, Andrew M. Brunner, Alexandra-Chloé Villani

Blood (2023) 142 (Supplement 1): 4319.

https://doi.org/10.1182/blood-2023-189858

Published: 2023

Journal Articles

A Phase 2 Study of Lenalidomide in Combination with Mitoxantrone, Etoposide, and Cytarabine (Len plus MEC) in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Manik Razdan Kuchroo, Robert A. Redd, Jacqueline S. Garcia, Michael Keng, Gabriela S. Hobbs, Jacalyn Rosenblatt, Marlise R. Luskin, Rupa Narayan, Philip C. Amrein, Malgorzata McMasters, Martha Wadleigh, Hanno Hock, Richard Stone, Donna S. Neuberg, David Avigan, Karen K. Ballen, Amir T. Fathi, Daniel J. DeAngelo, Andrew M. Brunner

Blood (2023) 142 (Supplement 1): 2894.

https://doi.org/10.1182/blood-2023-188182

Published: 2023

Journal Articles

Changes in White Blood Cell Counts Early during Treatment of Acute Leukemia Using Differentiating Chemotherapies

Amyah C. Harris, Christopher S. Bell, Gabriela S. Hobbs, Hanno Hock, Philip C. Amrein, Rupa Narayan, Amir T. Fathi, Andrew M. Brunner

Blood (2023) 142 (Supplement 1): 1486.

https://doi.org/10.1182/blood-2023-187367

Published: 2023

Journal Articles

Phase I Study of Ixazomib with Conventional Chemotherapy in the Treatment of Acute Myeloid Leukemia in Older Adults

Blood (2022) 140 (Supplement 1): 3309–3311.

https://doi.org/10.1182/blood-2022-160100

Published: 2022

Journal Articles

A Phase 2 Randomized Study Comparing Venetoclax and Azacitidine to Conventional Induction Chemotherapy for Newly Diagnosed Fit Adults with Acute Myeloid Leukemia

Amir T. Fathi, Geoffrey G Fell, Areej El-Jawahri, Alexander E. Perl, Brian A. Jonas, Ajoy L. Dias, Alice S. Mims, Uma Borate, Brittany Knick Ragon, Michael R. Grunwald, Mary Linton B. Peters, Timothy A. Graubert, Philip C. Amrein, Hanno R. Hock, Andrew M. Brunner, Gabriela S. Hobbs, Rupa Narayan, Donna S. Neuberg, Ibrahim Aldoss

Blood (2022) 140 (Supplement 1): 3284–3286.

https://doi.org/10.1182/blood-2022-162525

Published: 2022

Journal Articles

Inhibition of ATR with AZD6738 (Ceralasertib) for the Treatment of Progressive or Relapsed Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: Safety and Preliminary Activity from a Phase Ib/II Study

Andrew M. Brunner, Yiwen Liu, Lourdes M. Mendez, Jacqueline S. Garcia, Philip C. Amrein, Donna S. Neuberg, Emma Dean, Simon Smith, Richard M. Stone, Amir T. Fathi, Matthew J. Walter, Timothy A. Graubert, Meagan A. Jacoby

Blood (2021) 138 (Supplement 1): 1521.

https://doi.org/10.1182/blood-2021-147301

Published: 2021

Journal Articles

Concurrent FLT3 Inhibitor and IDH Inhibitor Therapy in Patients with Acute Myeloid Leukemia (AML)

Amir T. Fathi, Alexander E. Perl, MD, Mark Levis, MD PhD, Catherine C. Smith, MD, Andrew M. Brunner, Koichi Takahashi, MD PhD, Philip C. Amrein, MD, Hanno R. Hock, MD PhD, Gabriela S. Hobbs, MD, Rupa Narayan, Jenna A. Moran, NP, Meghan Bergeron, NP, Julia E. Foster, NP, Naval Daver, MD, Courtney D. DiNardo, MD MSCE

Blood (2020) 136 (Supplement 1): 11–12.

https://doi.org/10.1182/blood-2020-140118

Published: 2020

Journal Articles

Phase I Study of Ixazomib Added to Chemotherapy in the Treatment of Acute Lymphoblastic Leukemia in Older Adults

Blood (2020) 136 (Supplement 1): 41–42.

https://doi.org/10.1182/blood-2020-139661

Published: 2020

Journal Articles

Phase I Study of Ixazomib with Conventional Chemotherapy in the Treatment of Acute Myeloid Leukemia in Older Adults

Blood (2020) 136 (Supplement 1): 7–8.

https://doi.org/10.1182/blood-2020-140584

Published: 2020

Journal Articles

A Phase 1 Trial of Regorafenib in Advanced Myeloid Malignancies

Chi-Joan How, MD, Siyang Ren, Jennifer Lombardi Story, Meghan Bergeron, NP, Julia E. Foster, NP, Philip C. Amrein, MD, Andrew M. Brunner, Amir T. Fathi, Hanno R. Hock, MD PhD, Jenna A. Moran, NP, Rupa Narayan, Donna S. Neuberg, ScD, Aura Y. Ramos, RN, Tina T. Som, RN, Megan Vartanian, RN, Yi-Bin Chen, MD, Gabriela S. Hobbs, MD

Blood (2020) 136 (Supplement 1): 5–6.

https://doi.org/10.1182/blood-2020-140278

Published: 2020

Journal Articles

A Phase I Study of the IDH2 Inhibitor Enasidenib As Maintenance Therapy for IDH2 -Mutant Myeloid Neoplasms Following Hematopoietic Cell Transplantation

Blood (2020) 136 (Supplement 1): 4–5.

https://doi.org/10.1182/blood-2020-140176

Published: 2020

Journal Articles

Phase I Study of Ixazomib in Addition to Chemotherapy for the Treatment of Acute Myeloid Leukemia in Older Adults

Blood (2018) 132 (Supplement 1): 4059.

https://doi.org/10.1182/blood-2018-99-117566

Published: 2018

Journal Articles

Phase I Study of Ixazomib in Addition to Chemotherapy for the Treatment of Acute Lymphoblastic Leukemia in Older Adults

Blood (2018) 132 (Supplement 1): 2704.

https://doi.org/10.1182/blood-2018-99-117506

Published: 2018

Journal Articles

Clinical Outcomes Following Frontline Chemotherapy for Patients with Myeloid Malignancies Harboring Splicing Factor Mutations

Evan C. Chen, MD, Gabriela S. Hobbs, MD, Philip C. Amrein, MD, Timothy A. Graubert, MD, Amir T. Fathi, MD, Andrew M. Brunner, MD

Blood (2018) 132 (Supplement 1): 4364.

https://doi.org/10.1182/blood-2018-99-111982

Published: 2018

Journal Articles

Efficacy of Lenalidomide and Bortezomib for Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) Relapsing after Allogeneic Stem Cell Transplantation

Andrew M. Brunner, MD, Traci M. Blonquist, MS, Malgorzata McMasters, MD, Gabriela S. Hobbs, MD, Steven L McAfee, MD, Jacalyn Rosenblatt, MD, Philip C. Amrein, MD, Christine Connolly, Aura Y. Ramos, Kaleb Mikami, Emma Logan, Bimalangshu R Dey, MD, Thomas Spitzer, MD, David E. Avigan, MD, Yi-Bin Chen, MD, Karen K. Ballen, MD, Areej El-Jawahri, MD, Amir T. Fathi, MD

Blood (2018) 132 (Supplement 1): 4587.

https://doi.org/10.1182/blood-2018-99-110559

Published: 2018

NARROW

Clinical Activity and Safety of the Oral ATR Inhibitor Ceralasertib (AZD6738) in Patients with MDS or CMML after Prior HMA Therapy

Retrospective Single-Institution Review of Bosutinib Dose Optimization for Efficacy and Safety with Dose Ramp-up and Titration

CDK9 Inhibition Sensitizes TP53 Mutated AML to Standard Chemotherapy

TRK Protein Expression in TP53 Altered Acute Erythroid Leukemia

Safety and Activity of the TIM3 Inhibitor Sabatolimab in Patients with Lower-Risk Myelodysplastic Syndromes

Single-Cell Multiomics Analysis Reveals Potential Drivers of Response to the Anti-TIM3 Inhibitor Sabatolimab Combined with Azacitidine in MDS and CMML

A Phase 2 Study of Lenalidomide in Combination with Mitoxantrone, Etoposide, and Cytarabine (Len plus MEC) in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Changes in White Blood Cell Counts Early during Treatment of Acute Leukemia Using Differentiating Chemotherapies

Phase I Study of Ixazomib with Conventional Chemotherapy in the Treatment of Acute Myeloid Leukemia in Older Adults

A Phase 2 Randomized Study Comparing Venetoclax and Azacitidine to Conventional Induction Chemotherapy for Newly Diagnosed Fit Adults with Acute Myeloid Leukemia

Inhibition of ATR with AZD6738 (Ceralasertib) for the Treatment of Progressive or Relapsed Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: Safety and Preliminary Activity from a Phase Ib/II Study

Concurrent FLT3 Inhibitor and IDH Inhibitor Therapy in Patients with Acute Myeloid Leukemia (AML)

Phase I Study of Ixazomib Added to Chemotherapy in the Treatment of Acute Lymphoblastic Leukemia in Older Adults

Phase I Study of Ixazomib with Conventional Chemotherapy in the Treatment of Acute Myeloid Leukemia in Older Adults

A Phase 1 Trial of Regorafenib in Advanced Myeloid Malignancies

A Phase I Study of the IDH2 Inhibitor Enasidenib As Maintenance Therapy for IDH2 -Mutant Myeloid Neoplasms Following Hematopoietic Cell Transplantation

Phase I Study of Ixazomib in Addition to Chemotherapy for the Treatment of Acute Myeloid Leukemia in Older Adults

Phase I Study of Ixazomib in Addition to Chemotherapy for the Treatment of Acute Lymphoblastic Leukemia in Older Adults

Clinical Outcomes Following Frontline Chemotherapy for Patients with Myeloid Malignancies Harboring Splicing Factor Mutations

Efficacy of Lenalidomide and Bortezomib for Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) Relapsing after Allogeneic Stem Cell Transplantation

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only